Costa L.J.,Medical University of South Carolina |
Zhang M.-J.,Medical College of Wisconsin |
Zhong X.,Medical College of Wisconsin |
Lonial S.,Emory University |
And 18 more authors.
Biology of Blood and Marrow Transplantation | Year: 2013
The impact of novel drugs for treating multiple myeloma (MM) on the utilization and outcomes of autologous hematopoietic progenitor cell transplantation (AHPCT) is unknown. We reviewed characteristics and outcomes of 20,278 patients who underwent AHPCT within 12months of diagnosis of MM in the United States and Canada and registered at the Center for International Blood and Marrow Transplant Research (CIBMTR) in 3 time cohorts reflecting the increasing availability of novel drugs: 1995 to 1999 (n=2226), 2000 to 2004 (n=6408), and 2005 to 2010 (n=11,644). In the United States, the number of AHPCTs performed increased at a greater rate than new MM cases. Patients in recent cohorts were older, less likely to have stage 3MM, and more likely to have received previous thalidomide, lenalidomide, or bortezomib. On multivariate analysis, AHPCT in the 2000 to 2004 cohort (HR=0.77) or in the 2005 to 2010 cohort (HR=0.68) were associated with lower risk of death. Survival at 60months post-AHPCT improved from 47% in 1995 to 1999 to 55% in 2000 to 2004 and to 57% in 2005 to 2010, owing less to improvement in progression-free survival (50% versus 55% versus 57% at 24months) than to postrelapse/progression survival (58% versus 65% versus 72% at 24months). AHPCT and new biological agents are complementary, nonredundant therapies and should be combined in the management of MM in suitable patients. © 2013 American Society for Blood and Marrow Transplantation.
Van Dooren A.,Sportmax |
Beelen M.,Sportmax |
Haak H.R.,Interne Geneeskunde |
Sport en Geneeskunde | Year: 2014
A well known problem in patients with diabetes mellitus type 1 (DM-I), is the occurrence of hypoglycaemia during or after exercise. Less known in this population is the development of hyperglycaemia due to physical exercise, and the possible preventive effect of carbohydrate ingestion. Hyperglycaemia in exercise can be caused by a large rise in catecholamine levels which stimulates glycogenosis. In addition, catecholamine inhibits the release of insulin. In healthy athletes, the catecholamine levels drop after exercise, resulting in a compensatory increase of insulin. On the contrary, this does not occur in DM-I patients, which could lead to continuation of hyperglycaemia. Ingesting carbohydrates has the potential to protect against this, due to an inhibiting effect on catecholamine release, as proven in healthy subjects. Whether this applies for DM-I patients as well needs further investigation. We describe a case in which substantial hyperglycaemia occurred during exercise and in which ingestion of carbohydrates led to improvement of glycemic control.
Freytes C.O.,University of Texas Health Science Center at San Antonio |
Vesole D.H.,Hackensack University Medical Center |
Lerademacher J.,Medical College of Wisconsin |
Zhong X.,Medical College of Wisconsin |
And 10 more authors.
Bone Marrow Transplantation | Year: 2014
There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or reduced-intensity conditioning (NST/RIC) in 289 subjects reported to the CIBMTR from 1995 to 2008. NST/RIC recipients were younger (median age 53 vs 56 years; P<0.001) and had a shorter time to progression after their first autotransplant. Non-relapse mortality at 1-year post transplant was higher in the NST/RIC cohort, 13% (95% confidence interval (CI), 8-19) vs 2% (95% CI, 1-5, P≤0.001). Three-year PFS and OS for the NST/RIC cohort were 6% (95% CI, 3-10%) and 20% (95% CI, 14-27%). Similar outcomes for the autotransplant cohort were 12% (95% CI, 7-19%, P=0.038) and 46% (95% CI, 37-55%, P=0.001). In multivariate analyses, risk of death was higher in NST/RIC recipients (hazard ratio (HR) 2.38 (95% CI, 1.79-3.16), P<0.001), those with Karnofsky performance score<90 (HR 1.96 (95% CI, 1.47-2.62), P<0.001) and transplant before 2004 (HR 1.77 (95% CI, 1.34-2.35) P≤0.001). In conclusion, NST/RIC was associated with higher TRM and lower survival than an autotransplant. As disease status was not available for most allotransplant recipients, it is not possible to determine which type of transplant is superior after autotransplant failure. © 2014 Macmillan Publishers Limited. All rights reserved.
PubMed | Hackensack University Medical Center, Roswell Park Cancer Institute, Imperial College London, Mayo Medical School and 7 more.
Type: Comparative Study | Journal: Bone marrow transplantation | Year: 2014
There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or reduced-intensity conditioning (NST/RIC) in 289 subjects reported to the CIBMTR from 1995 to 2008. NST/RIC recipients were younger (median age 53 vs 56 years; P<0.001) and had a shorter time to progression after their first autotransplant. Non-relapse mortality at 1-year post transplant was higher in the NST/RIC cohort, 13% (95% confidence interval (CI), 8-19) vs 2% (95% CI, 1-5, P0.001). Three-year PFS and OS for the NST/RIC cohort were 6% (95% CI, 3-10%) and 20% (95% CI, 14-27%). Similar outcomes for the autotransplant cohort were 12% (95% CI, 7-19%, P=0.038) and 46% (95% CI, 37-55%, P=0.001). In multivariate analyses, risk of death was higher in NST/RIC recipients (hazard ratio (HR) 2.38 (95% CI, 1.79-3.16), P<0.001), those with Karnofsky performance score<90 (HR 1.96 (95% CI, 1.47-2.62), P<0.001) and transplant before 2004 (HR 1.77 (95% CI, 1.34-2.35) P0.001). In conclusion, NST/RIC was associated with higher TRM and lower survival than an autotransplant. As disease status was not available for most allotransplant recipients, it is not possible to determine which type of transplant is superior after autotransplant failure.
Is the lack of sensitivity and specificity of the assay for total protein in urine the reason for missing monoclonal gammopathy? [Het gebrek aan sensitiviteit en specificiteit van de totaaleiwitbepaling voor de detectie van monoklonale vrije lichte ketens in urine]
Brinkman J.W.,Klinisch Chemisch Laboratorium |
Ijpelaar D.H.T.,Interne Geneeskunde |
Schrander-van Der Meer A.M.,Interne Geneeskunde |
Jonkers G.J.P.M.,Interne Geneeskunde |
Beijer C.,Klinisch Chemisch Laboratorium
Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde | Year: 2011
Clinical laboratories play an essential role in the study of monoclonal gammopathies. Because of the complexity, guidelines have been published containing recommendations on implementation and interpretation of this laboratory investigation. In The Netherlands, the CBO (Dutch Institute for Healthcare Improvement) guideline 'Monoclonal Gammopathy' with recommendations on screening and follow-up research for paraproteins in both serum and urine is often used. Although this guideline is practical for most cases it is not for our case. Specifically, the CBO guideline recommends analysis of monoclonal free light chains in urine when the concentration of total protein in urine is above 200 mg/L. However, the currently used total protein assays in urine reportedly appear neither sensitive nor specific enough, missing the diagnosis; in agreement with classical findings of Brigden et al. (1990).
Djelantik M.,Universitair Medisch Centrum Utrecht |
Bloemkolk D.,Tergooi Ziekenhuis |
Tijdink J.,Interne Geneeskunde
Tijdschrift voor Psychiatrie | Year: 2015
Wernicke encephalopathy is an acute neuropsychiatric disease with heterogeneous symptoms, including changes in mental status, ataxia and ocular abnormalities; if left untreated, these symptoms can lead to morbidity and even to mortality.The treatment is thiamine suppletion. Because of the heterogeneity of the symptoms and the high risk of morbidity and mortality if the symptoms are not treated, it is vitally important that on observing a patient's early symptoms the clinician immediately suspects that the symptoms could point to Wernicke encephalopathy.
Increased urinary levels of metanephrines with methylphenidate use can lead to suspicion of a pheochromocytoma [Verhoogde concentraties metanefrines in urine bij methylfenidaat gebruik kan leiden tot verdenking feochromocytoom]
Man W.H.,Universitair Medisch Centrum |
Hagen C.E.C.,Interne Geneeskunde |
Wielders J.P.M.,Klinische Chemie |
Malingre M.M.,Universitair Medisch Centrum
Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde | Year: 2014
Increased catecholamine and metanephrine levels in urine and blood are characteristic features of a pheochromocytoma. These increased levels of catecholamines can result in hypertension, palpitations and an increased heart rate. We describe a 41-year old obese man with severe hypertension. He was treated successfully with antihypertensive drugs. For treatment of ADHD methylphenidate was started. The hypertension deteriorated. Laboratory tests showed increased urinary metanephrine and normetanephrine levels. After withdrawal of methylphenidate metanephrine levels normalized. After restart of methylphenidate, only normetanephrine levels increased again. The blood pressure did not change. Use of methylphenidate and a pheochromocytoma can both result in increased urinary levels of metanephrines. In the diagnostic pathway for pheochromocytoma based on catecholamine and metanephrine-levels, next to effects of dietary components, also effects of medication should be excluded. © 1997-2014 Nederlandse V ereniging voor Klinische Chemie en Laboratoriumgeneeskunde.
Hunfeld N.,Ziekenhuisapotheker in Opleiding |
Evers D.,Interne Geneeskunde |
Van Hest R.,Ziekenhuisapotheker in Opleiding |
Pharmaceutisch Weekblad | Year: 2010
Objective: This case report describes renal failure in a 71 year old male with multiple myeloma, stage IIA, after administration of bortezomib and erythromycin. We considered the possibility of an interaction between bortezomib and erythromycin. Design and methods: Description of the case and literature search. Results: During the first cycle of bortezomib, the patient showed a decrease in renal clearance (creatinin increased from 150 to 370 μmol/l). Renal function recovered within a week. Bortezomib was then continued at a reduced dose of 50%. Two days before the fourth administration, the patient developed fever. Erythromycin was started (500 mg p.o. four times daily), creatinin was still 150 μmol/l. One week later, the patient developed renal failure (creatinin 541 μmol/l) and was diagnosed with tubulo-interstitial nephritis caused by bortezomib toxicity likely based on an interaction with erythromycin. There is no information about this interaction in literature, but its occurrence can be explained by effects on CYP3A4 metabolism. Erythromycin is a moderate CYP3A4 inhibitor and substrate and bortezomib is a CYP3A4 substrate. Conclusion: We recommend frequent monitoring (serum creatinin on day 3/4 and day 7/8) of renal function in patients during and after administration of bortezomib in combination with a CYP3A4 inhibitor.
Implementation of the Muitidisciplinary guideline predialysis regarding metabolic acidosis in VieCuri Medical Center: 2013 compared with 2012 [Implementatie van de Multidisciplinaire richtlijn predialyse bij predialysepatienten met metabole acidose in VieCuri MC: 2013 vergeleken met 2012]
Burgers D.M.T.,Klinische Farmacie |
Van Dijk E.A.,Klinische Farmacie |
Oldenhof N.J.J.,Klinische Farmacie |
Funnekotter-Van Der Snoek M.A.,Klinische Farmacie |
Hermans M.M.H.,Interne Geneeskunde
Pharmaceutisch Weekblad | Year: 2015
OBJECTIVE: To compare the degree of implementation of the Muitidisci-plinary guideline predialysis regarding metabolic acidosis in 2013 to 2012 in VieCuri Medical Center. DESIGN: Retrospective and prospective observational study. METHODS: Adult predialysis patients were included in VieCuri Medical Center in 2012 and 2013. For each patient the measurement of the bicarbonate level has been checked. Also the presence of alkali therapy in patients with metabolic acidosis (bicarbonate level < 22 mmol/L) has been checked. Alkali therapy could consist of sodium bicarbonate tablets or sodium lactate solution. Chi-square tests were performed to test to what extent the guideline was followed in 2013 compared to 2012. Side effects and ease of use as secondary outcomes were prospectively measured by a questionnaire. Effectiveness as a secondary outcome was measured by the laboratory value of bicarbonate. This value has been checked before and after starting alkali therapy. RESULTS: Patient populations were comparable in 2012 and 2013. The bicarbonate level was measured in 48% of the patients in 2012 against 39% in 2013 (P = 0.021). Alkali therapy was more often started in patients with metabolic acidosis in 2013 (44%) com-pared to 2012 (22%) (P = 0.011). CONCLUSION: Despite alkali therapy was more often started in predialysis patients with metabolic acidosis than in 2012, the Muitidisci-plinary guideline predialysis regarding metabolic acidosis is still insufficiently followed in 2013 in VieCuri Medical Center.
Herpers R.,Klinisch Chemisch en Hematologisch Laboratorium |
Van Rossum A.P.,Klinisch Chemisch en Hematologisch Laboratorium |
Vlasveld L.Th.,Interne Geneeskunde |
Castel A.,Klinisch Chemisch en Hematologisch Laboratorium
Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde | Year: 2013
Carcinoid tumors belong to the group of neuroendocrine tumors and are characterized by the secretion of amines and peptide hormones like 5-hydroxytryptophan, serotonin, bradykinine, tachykinine and prostaglandin. Carcinoid syndrome refers to symptoms like flushing and chronic diarrhea which usually only arise after metastatic spread of the primary tumor towards the liver, whereby the secreted peptides escape metabolic degradation in the enterohepatic circulation. Laboratory diagnostics of carcinoid tumors focuses primarily on the detection of the secreted peptides and their derivatives. Testing for serotonin, 5-hydroxyindoleacetic acid (5-HIAA) and chromogranin A (CgA) is most widespread, with CgA being the marker of first choice based on its sensitivity in screening for the presence of neuroendocrine tumors. In this review we discuss the clinical aspects and a range of markers available for the biochemical screening for carcinoid tumors as well as their pitfalls, illustrated by several recent cases found in the Bronovo Hospital.